-
Aug 18, 2026
-
Thomas Scientific today announced that Jeff Hrush has joined the company as Senior Vice President, Technical Sales.
Aug 19, 2026
-
ECI announced today that its Product & Packaging Testing Laboratory, located in the Coyol Free Zone in Costa Rica, has achieved ISO/IEC 17025:2017 accreditation from A2LA for technical competence in mechanical testing.
Aug 10, 2026
-
Sanofi’s MenQuadfi has received European Commission approval for use in infants from six weeks of age against invasive meningococcal disease caused by serogroups A, C, W and Y.
The expanded indication is supported by the MET58 pivotal study and clinical data involving more than 6,000 infants across 11 countries.
The approval provides EU healthcare professionals with another option for early protection against a rapidly progressing and potentially fatal infection.
Aug 9, 2026
-
CellCarta today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM).
Aug 5, 2026
-
Regulatory milestone advances Proscia’s open approach to digital pathology
Aug 5, 2026
-
Verista names seasoned healthcare and pharma services leader as CEO to drive strategic growth, innovation, and operational excellence.
Jul 30, 2026
-
Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration
Jul 21, 2026
-
Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that Lilly’s GLP-1 advertising campaigns use outdated comparisons and mislead consumers about obesity and diabetes treatments.
The dispute focuses on advertisements comparing Zepbound® and Mounjaro® with lower doses of Wegovy® and Ozempic®.
Novo Nordisk is seeking removal of the campaigns and corrective advertising to ensure patients receive updated scientific information.
The case highlights increasing competition between leading pharmaceutical companies in the fast-growing GLP-1 therapy market.
Jul 21, 2026
-
Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion, including milestone-based payments. The acquisition significantly expands Lilly's neuroscience pipeline with innovative rapid-acting neuroplastogen therapies for treatment-resistant depression and other serious mental health disorders. The transaction highlights growing pharmaceutical investment in next-generation psychiatric medicines designed to deliver durable symptom relief through novel mechanisms of action.
Jul 20, 2026
-
Trajan Scientific and Medical (Trajan), a global developer and manufacturer of analytical, life sciences, and medical technologies, has announced that its Harpera™ Microbiopsy Punch is now FDA-registered for marketing in the US. Previously available in the country for investigational use only, the suture-free device can now be used by healthcare professionals across a broader range of clinical skin sampling applications, alongside clinical research and wellness programs.
The registration responds to growing demand from healthcare and research organizations for patient-friendly sampling approaches, offering a minimally invasive alternative to traditional skin biopsy that reduces collection burden while preserving sample quality for modern molecular techniques. Healthcare professionals in the US now gain expanded access to a tool that supports dermatology, biomarker research, and precision medicine, with applications spanning molecular analysis, translational research, and longitudinal skin sampling.
Jul 19, 2026
-
Creative Diagnostics announces Hantavirus Research Reagents and Products to support hantavirus research and diagnostic assay development.
Jul 14, 2026
-
• Strengthens multiomics portfolio offering metabolite-level insight to connect molecular data with biological function across broader life science studies
• New workflow built around Thermo Scientific Vanquish UHPLC coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry
Jul 12, 2026
-
The FDA has approved Sanofi's Sarclisa Escena, making it the first anticancer therapy that can be administered through a wearable on-body injector. Clinical studies showed the new subcutaneous treatment delivers effectiveness comparable to intravenous therapy while reducing administration time and infusion-related reactions. The approval is expected to improve both patient convenience and healthcare workflow in the treatment of multiple myeloma.
Jul 12, 2026
-
Novartis has agreed to acquire UK-based biotech company Myricx Bio in a deal worth up to USD 1.5 billion to strengthen its oncology pipeline. The acquisition brings Myricx's next-generation NMTi antibody-drug conjugate (ADC) platform, designed to overcome resistance to existing cancer therapies. It also adds two lead ADC candidates targeting B7-H3 and HER2, expanding Novartis' portfolio for treating solid tumors. The transaction is expected to close in the second half of 2026, subject to regulatory approvals.
Jul 5, 2026
-
Jul 7, 2026
-
ECI has announced the appointment of Taranjit S. Samra, DRSc, MSEE, RAC, as Head of Medical Device Software Engineering, Cybersecurity and AI.
Jul 6, 2026
-
Jul 1, 2026
-
Enhancements further break down silos and reduce fragmentation through integrated risk and quality management within one clinical data intelligence platform
Jun 28, 2026
-
Jun 22, 2026